Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Tachykinin antagonists in early development at Pfizer

Feb. 17, 1999

Celexa approved in Canada

Feb. 17, 1999

Astra discloses novel neuronal N-type calcium channel ligands

Feb. 16, 1999

New agents for prion diseases available for licensing from NIH

Feb. 16, 1999

Promising results obtained with activated immune cell therapies in development at Proneuron

Feb. 15, 1999

New formulation of Zofran receives marketing clearance in the U.S.

Feb. 15, 1999

Mitsubishi antidepressant to be codeveloped by Taisho

Feb. 12, 1999

New compounds from Novo Nordisk for pain, inflammation, diabetes

Feb. 12, 1999

Astra describes N-type neuronal calcium channel blockers and their use

Feb. 12, 1999

Orally bioavailable tachykinin antagonists from MS&D for emesis, etc.

Feb. 12, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld
Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...